Biomarkers
Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation
Cancer 2023 April 12 [Link] Yaniv Berger, Meghana Gadiraju, Ankit Dhiman, Katie Gilliam, Buerkley Opalecky, Heather Chen, Maria Helgeson, Oliver S Eng, Aliya N Husain, Michael W Drazer, Hedy L Kindler, Jane E Churpek, Kiran K Turaga Abstract Background: This study aimed to investigate if peritoneal mesothelioma (PM) patients with germline mutations (GM) have distinct…
Read MoreDamage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy
Frontiers in Immunology 2023 March 24 [Link] Zheng Liu, Rui Wan, Hua Bai, Jie Wang Abstract Objectives: Malignant pleural mesothelioma (MPM) is characterized as an incredibly aggressive form of cancer with a dismal diagnosis and a dearth of specific biomarkers and therapeutic options. For MPM patients, the effectiveness of immunotherapy may be influenced by damage-associated…
Read MoreExcess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma
Frontiers in Immunology 2023 March 24 [Link] Mégane Willems, Arnaud Scherpereel, Eric Wasielewski, Jo Raskin, Hélène Brossel, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Majeed Jamakhani, Vincent Heinen, Renaud Louis, Bernard Duysinx, Malik Hamaidia, Luc Willems Abstract Background: Only a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the…
Read MoreThe cytological features of effusions with mesothelioma in situ: A report of 9 cases
Diagnostic Cytopathology 2023 March 21 [Link] Claire W Michael, Carlos C W M Bedrossian, Navid Sadri, Sonja Klebe Abstract Introduction: The diagnosis of mesothelioma in situ (MIS) is now accepted by the WHO as a pre-invasive neoplastic mesothelial proliferation and considered a diagnosis based on histologic evaluation only. Although the definition of MIS includes recurrent…
Read MoreTROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
Lung Cancer 2023 April [Link] Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedüs Abstract Objectives: Malignant pleural mesothelioma (MPM) is an aggressive cancer which at large is not amenable to curative surgery. Despite the recent approval of immune checkpoint…
Read MoreThe Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2023 February 22 [Link] Maxime Borgeaud, Floryane Kim, Alex Friedlaender, Filippo Lococo, Alfredo Addeo, Fabrizio Minervini Abstract Malignant pleural mesothelioma (MPM) is a rare cancer usually caused by asbestos exposure and associated with a very poor prognosis. After more than a decade without new therapeutic options, immune checkpoint inhibitors (ICIs) demonstrated…
Read MoreA novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma
Pathology 2023 February 4 [Link] Yagiz Aksoy, Angela Chou, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa S Ahadi, Anthony J Gill, Talia L Fuchs Abstract Recent advances in the management of diffuse pleural mesothelioma (DPM) have increased interest in prognostication and risk stratification on the basis that maximum benefit of combination immunotherapy appears to be…
Read MoreSmall RNA-Seq Transcriptome Profiling of Mesothelial and Mesothelioma Cell Lines Revealed microRNA Dysregulation after Exposure to Asbestos-like Fibers
Biomedicines 2023 February 13 [Link] Veronica Filetti, Claudia Lombardo, Carla Loreto, George Dounias, Massimo Bracci, Serena Matera, Lucia Rapisarda, Venerando Rapisarda, Caterina Ledda, Ermanno Vitale Abstract Environmental exposure to fibers of respirable size has been identified as a risk for public health. Experimental evidence has revealed that a variety of fibers, including fluoro-edenite, can develop…
Read MoreMedical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma
Proceedings of the Japan Academy 2023 [Link] Shoutaro Tsuji, Kohzoh Imai Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleural cavity. Pathologically distinguishing MPM from other pleural lesions is often difficult. We searched for marker antigens to facilitate the pathological diagnosis of MPM and found useful markers for the pathological detection of…
Read MoreIdentification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics
Cancers 2023 January 19 [Link] Nicolai B Palstrøm, Martin Overgaard, Peter Licht, Hans C Beck Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated, highly aggressive cancer characterized by late-stage diagnosis and poor prognosis. Gold standards for diagnosis are pleural biopsy and cytology of pleural effusion (PE), both of which are limited by low sensitivity and…
Read More